Loading…
Clinical outcome of patients with pancreatic metastases from renal cell cancer
Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. Of 262 pat...
Saved in:
| Published in: | BMC cancer 2015-02, Vol.15 (1), p.46-46, Article 46 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03 |
| container_end_page | 46 |
| container_issue | 1 |
| container_start_page | 46 |
| container_title | BMC cancer |
| container_volume | 15 |
| creator | Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji |
| description | Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC.
Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed.
The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8-15.5 years) and 3.8 years (IQR, 2.1-5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2-12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P |
| doi_str_mv | 10.1186/s12885-015-1050-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4332740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1673792264</sourcerecordid><originalsourceid>FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03</originalsourceid><addsrcrecordid>eNp1kU1LxDAQhoMo7rr6A7xIj16qmTRp2osg6ycsetFzSNvEjbTNmrSK_96UrssuKIR8zTtPJu8gdAr4AiBLLz2QLGMxBhYDZjgme2gKlENMKOb7W_sJOvL-HWPgGc4O0YSwjJOUwBQ9zWvTmlLWke270jYqsjpayc6otvPRl-mW4dSWToWrMmpUJ30Yykfa2SZyqg2ZparDFFTKHaMDLWuvTtbrDL3e3b7MH-LF8_3j_HoRFzTFXUwLVfC0AuBaFzilPGd5wpmsGGEgmdKAc9B5DqzSuGBcppwSkkuiSo5phZMZuhq5q75oVFWGap2sxcqZRrpvYaURu5HWLMWb_RQ0SQinA-BmBBTG_gPYjQRvxOi3CH6LwW9BAuZ8XYezH73ynWiMH_yQrbK9F5DyhOeEpDRIYZSWznrvlN48BlgM7fwTf7b9zU3Gb_-SHzZynLI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1673792264</pqid></control><display><type>article</type><title>Clinical outcome of patients with pancreatic metastases from renal cell cancer</title><source>PubMed Central Free</source><source>Publicly Available Content (ProQuest)</source><creator>Yuasa, Takeshi ; Inoshita, Naoko ; Saiura, Akio ; Yamamoto, Shinya ; Urakami, Shinji ; Masuda, Hitoshi ; Fujii, Yasuhisa ; Fukui, Iwao ; Ishikawa, Yuichi ; Yonese, Junji</creator><creatorcontrib>Yuasa, Takeshi ; Inoshita, Naoko ; Saiura, Akio ; Yamamoto, Shinya ; Urakami, Shinji ; Masuda, Hitoshi ; Fujii, Yasuhisa ; Fukui, Iwao ; Ishikawa, Yuichi ; Yonese, Junji</creatorcontrib><description>Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC.
Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed.
The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8-15.5 years) and 3.8 years (IQR, 2.1-5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2-12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9-5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0-4.4 years), no disease progression was observed.
The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-015-1050-2</identifier><identifier>PMID: 25872621</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Carcinoma, Renal Cell - pathology ; Female ; Follow-Up Studies ; Humans ; Kidney Neoplasms - pathology ; Male ; Middle Aged ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - secondary ; Pancreatic Neoplasms - therapy ; Retrospective Studies ; Risk Factors ; Survival Analysis ; Treatment Outcome</subject><ispartof>BMC cancer, 2015-02, Vol.15 (1), p.46-46, Article 46</ispartof><rights>Yuasa et al.; licensee BioMed Central. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03</citedby><cites>FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25872621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuasa, Takeshi</creatorcontrib><creatorcontrib>Inoshita, Naoko</creatorcontrib><creatorcontrib>Saiura, Akio</creatorcontrib><creatorcontrib>Yamamoto, Shinya</creatorcontrib><creatorcontrib>Urakami, Shinji</creatorcontrib><creatorcontrib>Masuda, Hitoshi</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><creatorcontrib>Fukui, Iwao</creatorcontrib><creatorcontrib>Ishikawa, Yuichi</creatorcontrib><creatorcontrib>Yonese, Junji</creatorcontrib><title>Clinical outcome of patients with pancreatic metastases from renal cell cancer</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC.
Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed.
The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8-15.5 years) and 3.8 years (IQR, 2.1-5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2-12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9-5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0-4.4 years), no disease progression was observed.
The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes.</description><subject>Aged</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - secondary</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU1LxDAQhoMo7rr6A7xIj16qmTRp2osg6ycsetFzSNvEjbTNmrSK_96UrssuKIR8zTtPJu8gdAr4AiBLLz2QLGMxBhYDZjgme2gKlENMKOb7W_sJOvL-HWPgGc4O0YSwjJOUwBQ9zWvTmlLWke270jYqsjpayc6otvPRl-mW4dSWToWrMmpUJ30Yykfa2SZyqg2ZparDFFTKHaMDLWuvTtbrDL3e3b7MH-LF8_3j_HoRFzTFXUwLVfC0AuBaFzilPGd5wpmsGGEgmdKAc9B5DqzSuGBcppwSkkuiSo5phZMZuhq5q75oVFWGap2sxcqZRrpvYaURu5HWLMWb_RQ0SQinA-BmBBTG_gPYjQRvxOi3CH6LwW9BAuZ8XYezH73ynWiMH_yQrbK9F5DyhOeEpDRIYZSWznrvlN48BlgM7fwTf7b9zU3Gb_-SHzZynLI</recordid><startdate>20150212</startdate><enddate>20150212</enddate><creator>Yuasa, Takeshi</creator><creator>Inoshita, Naoko</creator><creator>Saiura, Akio</creator><creator>Yamamoto, Shinya</creator><creator>Urakami, Shinji</creator><creator>Masuda, Hitoshi</creator><creator>Fujii, Yasuhisa</creator><creator>Fukui, Iwao</creator><creator>Ishikawa, Yuichi</creator><creator>Yonese, Junji</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150212</creationdate><title>Clinical outcome of patients with pancreatic metastases from renal cell cancer</title><author>Yuasa, Takeshi ; Inoshita, Naoko ; Saiura, Akio ; Yamamoto, Shinya ; Urakami, Shinji ; Masuda, Hitoshi ; Fujii, Yasuhisa ; Fukui, Iwao ; Ishikawa, Yuichi ; Yonese, Junji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - secondary</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuasa, Takeshi</creatorcontrib><creatorcontrib>Inoshita, Naoko</creatorcontrib><creatorcontrib>Saiura, Akio</creatorcontrib><creatorcontrib>Yamamoto, Shinya</creatorcontrib><creatorcontrib>Urakami, Shinji</creatorcontrib><creatorcontrib>Masuda, Hitoshi</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><creatorcontrib>Fukui, Iwao</creatorcontrib><creatorcontrib>Ishikawa, Yuichi</creatorcontrib><creatorcontrib>Yonese, Junji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuasa, Takeshi</au><au>Inoshita, Naoko</au><au>Saiura, Akio</au><au>Yamamoto, Shinya</au><au>Urakami, Shinji</au><au>Masuda, Hitoshi</au><au>Fujii, Yasuhisa</au><au>Fukui, Iwao</au><au>Ishikawa, Yuichi</au><au>Yonese, Junji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome of patients with pancreatic metastases from renal cell cancer</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2015-02-12</date><risdate>2015</risdate><volume>15</volume><issue>1</issue><spage>46</spage><epage>46</epage><pages>46-46</pages><artnum>46</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC.
Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed.
The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8-15.5 years) and 3.8 years (IQR, 2.1-5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2-12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9-5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0-4.4 years), no disease progression was observed.
The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25872621</pmid><doi>10.1186/s12885-015-1050-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2015-02, Vol.15 (1), p.46-46, Article 46 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4332740 |
| source | PubMed Central Free; Publicly Available Content (ProQuest) |
| subjects | Aged Carcinoma, Renal Cell - pathology Female Follow-Up Studies Humans Kidney Neoplasms - pathology Male Middle Aged Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - mortality Pancreatic Neoplasms - secondary Pancreatic Neoplasms - therapy Retrospective Studies Risk Factors Survival Analysis Treatment Outcome |
| title | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A29%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20of%20patients%20with%20pancreatic%20metastases%20from%20renal%20cell%20cancer&rft.jtitle=BMC%20cancer&rft.au=Yuasa,%20Takeshi&rft.date=2015-02-12&rft.volume=15&rft.issue=1&rft.spage=46&rft.epage=46&rft.pages=46-46&rft.artnum=46&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-015-1050-2&rft_dat=%3Cproquest_pubme%3E1673792264%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b460t-4beb76d117ffb0647959375ad5251a5ef1091f9915df0b57a674229a2ec704d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1673792264&rft_id=info:pmid/25872621&rfr_iscdi=true |